◆英語タイトル：Adamis Pharmaceuticals Corp (ADMP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8011820
◆発行会社（調査会社）：
GlobalData
◆発行日：2017年12月13日
◆ページ数：30
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
Summary
Adamis Pharmaceuticals Corp (Adamis), formerly Cellegy Pharmaceuticals Inc is a biopharmaceutical company that offers therapies. The company develops and commercializes products in the therapeutic areas of allergy and respiratory diseases. Its pipeline product, epinephrine pre-filled syringe is developed for anaphylactic reactions such as insect stings, foods, medications and latex. Adamis also provides pipeline products such as APC-2000 for the treatment of bronchospasms; APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease; and APC-3000, an HFA inhaled nasal steroid product for the treatment of allergic rhinitis. The company provides its products for patients, physicians, and healthcare organizations. It has operations in Phoenix, Arizona. Adamis is headquartered in San Diego, California, the US.
Adamis Pharmaceuticals Corp (ADMP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Adamis Pharmaceuticals Corp, Medical Devices Deals, 2011 to YTD 2017 9
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Adamis Pharma Enters Into Licensing Agreement With 3M Company For Taper Dry Powder Inhaler Technology 11
Equity Offering 13
Adamis Pharma Raises USD17.3 Million in Public Offering of Shares 13
Adamis Pharma Raises USD11 Million in Private Placement of Units 15
Adamis Pharma Raises USD5 Million in Private Placement of Preferred Stock 17
Adamis Pharma Raises USD5 Million in Private Placement of Preferred Stock 18
Adamis Pharma Raises USD11.5 Million in Public Offering of Shares 19
Adamis Pharma Raises USD5 Million in Private Placement of Preferred Stock 21
Adamis Pharma Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For US$25.5 Million 22
Adamis Pharma Completes Final Tranche Of Private Placement Of Shares For US$0.5 Million 23
Debt Offering 24
Adamis Pharma Completes Private Placement Of Debentures For US$0.6 Million 24
Adamis Pharma Completes Private Placement Of Senior Convertible Note For US$0.5 Million 25
Adamis Pharma Completes Private Placement Of Senior Convertible Note Due 2013 For US$1 Million 26
Adamis Pharmaceuticals Corp – Key Competitors 27
Adamis Pharmaceuticals Corp – Key Employees 28
Adamis Pharmaceuticals Corp – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30
List of Tables
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Adamis Pharmaceuticals Corp, Deals By Therapy Area, 2011 to YTD 2017 8
Adamis Pharmaceuticals Corp, Medical Devices Deals, 2011 to YTD 2017 9
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Adamis Pharma Enters Into Licensing Agreement With 3M Company For Taper Dry Powder Inhaler Technology 11
Adamis Pharma Raises USD17.3 Million in Public Offering of Shares 13
Adamis Pharma Raises USD11 Million in Private Placement of Units 15
Adamis Pharma Raises USD5 Million in Private Placement of Preferred Stock 17
Adamis Pharma Raises USD5 Million in Private Placement of Preferred Stock 18
Adamis Pharma Raises USD11.5 Million in Public Offering of Shares 19
Adamis Pharma Raises USD5 Million in Private Placement of Preferred Stock 21
Adamis Pharma Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For US$25.5 Million 22
Adamis Pharma Completes Final Tranche Of Private Placement Of Shares For US$0.5 Million 23
Adamis Pharma Completes Private Placement Of Debentures For US$0.6 Million 24
Adamis Pharma Completes Private Placement Of Senior Convertible Note For US$0.5 Million 25
Adamis Pharma Completes Private Placement Of Senior Convertible Note Due 2013 For US$1 Million 26
Adamis Pharmaceuticals Corp, Key Competitors 27
Adamis Pharmaceuticals Corp, Key Employees 28
Adamis Pharmaceuticals Corp, Subsidiaries 29
